How to reduce HbA1c is one of the most common questions asked by people living with type 2 diabetes or prediabetes in the UK — but the answer requires an honest, evidence-based starting point. HbA1c reflects your average blood glucose over two to three months, meaning it is biologically impossible to produce a meaningful reduction within a single week. What you can do immediately is begin the consistent dietary, physical activity, and medication changes that will lower your daily blood glucose and, over the following weeks and months, drive a genuine improvement in your HbA1c result. This article explains how, using NHS and NICE-aligned guidance.

What HbA1c Measures and Why It Matters

HbA1c measures the proportion of glycated haemoglobin in red blood cells, reflecting average blood glucose over 2–3 months; a result of 48 mmol/mol or above diagnoses type 2 diabetes under NHS and WHO criteria.

HbA1c — glycated haemoglobin — is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin inside red blood cells. Because red blood cells live for approximately 90 to 120 days, the proportion of haemoglobin that has become glycated gives clinicians a reliable picture of longer-term glucose control, rather than a single snapshot in time.

In the UK, HbA1c is reported in millimoles per mole (mmol/mol). UK diagnostic practice follows WHO criteria, as adopted across the NHS: a result of 48 mmol/mol or above is used to diagnose type 2 diabetes. In people without symptoms, a second confirmatory test — either a repeat HbA1c or a fasting plasma glucose — is required before a diagnosis is made. A reading between 42 and 47 mmol/mol indicates non-diabetic hyperglycaemia (sometimes called prediabetes). HbA1c is not appropriate for diagnosing diabetes in pregnancy, in people with suspected type 1 diabetes, or in those with certain haemoglobin disorders.

It is also important to be aware that HbA1c can be unreliable or misleading in conditions that affect red cell turnover or haemoglobin structure — including haemolytic anaemia, iron-deficiency anaemia, haemoglobinopathies (such as sickle cell disease or thalassaemia), recent blood transfusion, advanced chronic kidney disease, and acute illness. In these situations, your clinical team may use alternative measures such as fructosamine or continuous glucose monitoring (CGM) profiles.

For most people already living with type 2 diabetes, NICE (NG28) recommends an individualised HbA1c target. A target of 48 mmol/mol is appropriate where it can be achieved safely without hypoglycaemia-causing medicines. A target of 53 mmol/mol is generally used for people on insulin or sulphonylureas, where the risk of hypoglycaemia is higher. Targets may be set higher in certain circumstances, for example in older people or those with significant comorbidities, and should always be agreed with your clinical team.

Elevated HbA1c is clinically significant because sustained high blood glucose damages blood vessels and nerves over time. This underpins the risk of long-term complications including:

• Cardiovascular disease (heart attack, stroke)

• Diabetic retinopathy (sight loss)

• Diabetic nephropathy (kidney disease)

• Peripheral neuropathy (nerve damage, particularly in the feet)

Understanding what HbA1c measures is the essential first step before exploring how to improve it. Crucially, because the test reflects a two-to-three-month average, meaningful reductions in HbA1c cannot realistically occur within a single week — a point that is important to address honestly and safely.

Key sources: NHS HbA1c test information; WHO guidance on HbA1c for diagnosis (as adopted in the UK); NICE NG28: Type 2 diabetes in adults — management.

Lifestyle Steps That Support Better Blood Sugar Control

Reducing refined carbohydrates, taking at least 150 minutes of moderate aerobic activity per week, and managing body weight are the most impactful lifestyle steps for improving blood glucose and, over weeks to months, lowering HbA1c.

While HbA1c itself cannot be reduced in a week, adopting consistent lifestyle changes can begin to lower daily blood glucose levels relatively quickly, and these improvements will be reflected in your HbA1c result over the following weeks and months. The NHS and NICE both emphasise structured lifestyle intervention as a cornerstone of diabetes prevention and management.

Dietary changes are among the most impactful steps you can take. Reducing your intake of refined carbohydrates and added sugars — such as white bread, sugary drinks, pastries, and processed cereals — helps to blunt post-meal glucose spikes. Paying attention to both the quantity and quality of carbohydrates, choosing lower glycaemic index (GI) foods, increasing dietary fibre, and eating regular, balanced meals can all contribute to more stable blood glucose throughout the day. The NHS Eatwell Guide, the NHS Diabetes Prevention Programme, and Diabetes UK all provide evidence-based dietary guidance tailored to people in the UK. Individualised support from a registered dietitian is particularly valuable if you have complex needs.

Physical activity plays an equally important role. Muscle contraction increases glucose uptake independently of insulin, meaning even a brisk 30-minute walk after meals can measurably reduce post-meal blood glucose. The UK Chief Medical Officers' (CMO) Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days; NICE (NG28) supports these recommendations for people with type 2 diabetes. If you are taking insulin or a sulphonylurea, speak to your diabetes team before significantly increasing your activity levels, as dose or carbohydrate adjustments may be needed to avoid hypoglycaemia.

Additional lifestyle factors worth addressing include:

• Weight management — even a 5–10% reduction in body weight can significantly improve insulin sensitivity and glucose control

• Alcohol reduction — alcohol can cause unpredictable blood glucose fluctuations, including delayed hypoglycaemia in people taking insulin or sulphonylureas; the UK low-risk drinking guidelines (no more than 14 units per week) apply

• Smoking cessation — smoking worsens insulin resistance and cardiovascular risk

• Sleep quality — poor sleep is associated with impaired glucose regulation

These changes work cumulatively. Consistency over weeks and months, rather than dramatic short-term effort, is what produces lasting improvements in HbA1c.

Key sources: UK Chief Medical Officers' Physical Activity Guidelines; NHS Eatwell Guide; NHS Diabetes Prevention Programme (NDPP); Diabetes UK dietary guidance; NICE NG28.

Medicines That Help Lower HbA1c Over Time

Metformin is the first-line medication for type 2 diabetes in the UK; all glucose-lowering medicines reduce HbA1c gradually over weeks to months, and no licensed medication produces a clinically meaningful reduction within a single week.

For many people, lifestyle changes alone are insufficient to achieve target HbA1c levels, and medication forms an important part of diabetes management. In the UK, prescribing decisions are guided by NICE guidelines (NG28 and subsequent updates), and all medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). You should only start, stop, or adjust diabetes medicines under the supervision of your GP or diabetes team.

Metformin remains the first-line pharmacological treatment for most people with type 2 diabetes. It works primarily by reducing hepatic glucose production (gluconeogenesis) and improving peripheral insulin sensitivity. It does not cause hypoglycaemia when used alone and has a well-established safety profile. Common side effects include gastrointestinal upset — nausea, diarrhoea, and abdominal discomfort — which are often reduced by taking the medication with food or using a modified-release formulation. Renal function (eGFR) should be checked before starting metformin and monitored regularly, as dose adjustment or cessation is required at lower eGFR thresholds (refer to the current Summary of Product Characteristics, SPC). Long-term use of metformin is associated with reduced vitamin B12 absorption; the MHRA advises that B12 levels should be monitored periodically, particularly if symptoms such as fatigue, numbness, or tingling develop.

When HbA1c remains above target despite metformin, NICE recommends considering additional agents. These include:

• SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) — reduce glucose reabsorption in the kidneys. Cardiovascular and renal protective benefits have been demonstrated for specific agents in specific populations; these are not a class-wide effect and are defined by individual NICE Technology Appraisals and each medicine's SPC. Common side effects include genital mycotic infections (thrush), which should be treated promptly and discussed with your GP or pharmacist. Importantly, SGLT-2 inhibitors carry a risk of diabetic ketoacidosis (DKA), which can occur even when blood glucose is only moderately elevated (euglycaemic DKA). The MHRA advises that SGLT-2 inhibitors should be temporarily stopped during acute serious illness and before major surgery (sick-day rules); patients should be educated to recognise DKA symptoms — including nausea, vomiting, abdominal pain, rapid or deep breathing, drowsiness, and a fruity smell on the breath — and to seek urgent medical attention if these occur.

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) — stimulate insulin secretion in a glucose-dependent manner and promote weight loss. Gastrointestinal side effects (nausea, vomiting, diarrhoea) are common, particularly when starting treatment. Rare but serious risks include pancreatitis; if you develop severe or persistent abdominal pain, stop the medicine and seek urgent medical review.

• DPP-4 inhibitors (e.g., sitagliptin) — enhance incretin activity to improve post-meal insulin response; generally well tolerated.

• Sulphonylureas (e.g., gliclazide) — stimulate insulin secretion; carry a risk of hypoglycaemia and weight gain.

• Insulin therapy — used when oral agents are insufficient, particularly in type 1 diabetes or advanced type 2 diabetes.

All glucose-lowering medicines reduce HbA1c gradually over weeks to months — not days. No licensed medication produces a clinically meaningful HbA1c reduction within a single week. Any product claiming otherwise should be treated with significant caution.

If you think you have experienced a side effect from any medicine, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Key sources: NICE NG28; MHRA Drug Safety Update on SGLT-2 inhibitors and risk of ketoacidosis; eMC SPCs for individual medicines; relevant NICE Technology Appraisals.

When to Speak to Your GP or Diabetes Team

Call 999 immediately if DKA is suspected; contact your GP promptly for persistent hyperglycaemia, hypoglycaemia symptoms, medication side effects, or any new foot problems, which require urgent review within 24 hours per NICE NG19.

Managing blood glucose and HbA1c should always involve your GP or specialist diabetes team, particularly if you are making significant changes to your diet, exercise routine, or medication. Self-management is encouraged, but it works best within a framework of professional support and regular monitoring.

Seek emergency care (call 999 or go to A&E immediately) if you or someone else has symptoms that may indicate diabetic ketoacidosis (DKA): these include nausea, vomiting, severe abdominal pain, rapid or deep breathing, drowsiness or confusion, and a fruity smell on the breath. DKA can occur in people taking SGLT-2 inhibitors even when blood glucose is only moderately elevated. Do not wait — DKA is a medical emergency.

You should contact your GP or diabetes nurse promptly if you experience any of the following:

• Symptoms of hypoglycaemia (low blood sugar) — shakiness, sweating, confusion, palpitations, or loss of consciousness, particularly if you are taking insulin or a sulphonylurea. For a mild hypo, treat immediately with 15–20 g of fast-acting carbohydrate (e.g., glucose tablets, a small glass of fruit juice, or sugary drink), wait 15 minutes, and repeat if needed. If you drive, follow DVLA guidance on diabetes and driving, and discuss recurrent hypoglycaemia with your team.

• Persistent hyperglycaemia — blood glucose readings that remain consistently high despite your current treatment.

• Unexplained weight loss, excessive thirst, or frequent urination — these may indicate poorly controlled or newly developing diabetes.

• Side effects from medication — such as persistent gastrointestinal symptoms, genital thrush (a common side effect of SGLT-2 inhibitors, requiring prompt treatment), or any symptoms that concern you.

• Foot problems — any new ulceration, wound, infection, swelling, discolouration, or change in sensation in the feet requires urgent review. NICE (NG19) recommends referral to the multidisciplinary diabetic foot care service within 24 hours for suspected active foot disease such as ulceration, infection, or ischaemia. Do not delay seeking help for foot problems.

If you have been told your HbA1c is elevated and you have not yet been referred to a structured education programme, ask your GP about the NHS Diabetes Prevention Programme (for non-diabetic hyperglycaemia/prediabetes), a DESMOND or X-PERT programme (for type 2 diabetes), or DAFNE (for type 1 diabetes). These evidence-based programmes provide practical, personalised support.

It is also worth noting that if you are searching for ways to reduce HbA1c very rapidly — for example, ahead of a medical assessment or insurance review — it is important to discuss this honestly with your clinical team. Attempting to manipulate results through extreme short-term measures is not safe and does not reflect your true metabolic health.

Key sources: NHS: Diabetic ketoacidosis (DKA); NHS: Hypoglycaemia self-management; NICE NG19: Diabetic foot problems — prevention and management; NHS diabetes education programmes.

Realistic Timescales for Reducing HbA1c Safely

Early reductions in daily blood glucose may appear within 2–4 weeks of lifestyle changes, but a meaningful HbA1c reduction typically takes 6–12 weeks to detect and a full 3-month retest to accurately reflect cumulative progress.

One of the most important things to understand about HbA1c is that it is biologically impossible to produce a meaningful reduction within a single week. Because the test measures the cumulative glycation of red blood cells over two to three months, even dramatic improvements in daily blood glucose will not be fully reflected in your HbA1c result for at least six to twelve weeks — and a complete picture typically takes three months.

That said, the rate of improvement can be meaningful when the right changes are made consistently. Research and clinical experience suggest the following general timescales:

• Within 2–4 weeks: Daily blood glucose readings (via finger-prick testing or continuous glucose monitoring) may begin to improve with dietary changes and increased physical activity.

• Within 6–8 weeks: Early reductions in HbA1c may become detectable, particularly if starting a new medication or making significant lifestyle changes.

• Within 3 months: A full HbA1c retest will reflect the cumulative impact of changes made over the preceding period. The degree of reduction depends on your baseline HbA1c, the treatments used, and individual factors. As a general guide, metformin typically reduces HbA1c by around 11 mmol/mol on average; reductions with other agents vary. Combined lifestyle and pharmacological intervention can produce reductions of 10–20 mmol/mol or more in many people, though individual results differ.

• Over 6–12 months: Sustained lifestyle changes, weight loss, and optimised medication can produce substantial and lasting improvements.

NICE (NG28) recommends measuring HbA1c every three to six months until levels are stable and targets are met, then every six months thereafter. Your GP or diabetes team will advise on the appropriate interval for you.

For people with very high baseline HbA1c levels, reductions should be gradual. Rapidly lowering HbA1c — particularly through aggressive insulin regimens — can paradoxically worsen diabetic retinopathy in the short term, a phenomenon recognised in clinical guidelines. If your treatment is being intensified, ensure you are up to date with NHS Diabetic Eye Screening and inform your team, so that appropriate monitoring can be arranged.

The most effective and safest approach is a steady, sustained commitment to the lifestyle and medical strategies outlined above, guided by your healthcare team. Setting realistic expectations not only protects your health but also supports long-term motivation and adherence.

Key sources: NICE NG28: Type 2 diabetes in adults — management; NHS Diabetic Eye Screening Programme; Royal College of Ophthalmologists Diabetic Retinopathy Guidelines.

Frequently Asked Questions